Value of immunohistochemical Ki-67 and p53 determinations as predictive factors of outcome in renal cell carcinoma

被引:105
作者
Rioux-Leclercq, N
Turlin, B
Bansard, JY
Patard, JJ
Manunta, A
Moulinoux, JP
Guillé, F
Ramée, MP
Lobel, B
机构
[1] Univ Rennes 1, Fac Med, Serv Urol, Rennes, France
[2] Univ Rennes 1, Serv Anat & Cytol Pathol, Grp Rech Therapeut Anticanc, CNRS,ESA 6027, Rennes, France
关键词
D O I
10.1016/S0090-4295(99)00550-6
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Nuclear grade and tumor stage are important prognostic factors in renal cell carcinoma, but tumors of similar stage and grade can exhibit a wide variation in biologic behavior and clinical outcome. In this retrospective study, we evaluated the immunologic markers, Ki-67 (MIB1) and p53, in 73 cases of conventional (clear cell) renal cell carcinoma and compared these markers with the accepted prognostic features of grade, stage, and tumor size in predicting outcome. Methods. Specimens of 73 renal cell carcinomas of different nuclear grade (20 Furhman I/II, 32 Fuhrman III, and 21 Fuhrman IV) and different stage (10 pT1, 23 pT2, 36 pT3, and 4 pT4) were immunostained with monoclonal antibodies against Ki-67 and p53. Results. Univariate statistical analysis showed that tumor size (P <0.001), nuclear grade (P <0.01), tumor stage (P <0.01), Ki-67 index (P <0.001), and p53 immunostaining (P <0.03) correlated significantly with a poor prognosis. A Ki-67 index of 20% was a powerful predictor of survival in all patients (P <0.00001), with strong predictive values. On multivariate analysis, the Ki-67 index and metastases were significant independent prognostic factors (P <0.02 and <0.01, respectively). Conclusions. Ki-67 immunostaining appeared to be an additional prognostic indicator of biologic aggressiveness in renal cell carcinoma. Immunohistochemical assessment of tumor antigens could be used to identify patients at high risk of tumor progression in addition to conventional prognostic factors. UROLOGY 55: 501-505, 2000. (C) 2000, Elsevier Science Inc.
引用
收藏
页码:501 / 505
页数:5
相关论文
共 51 条
[21]  
Herbst C, 1998, J CANCER RES CLIN, V124, P141
[22]  
Hindermann W, 1997, PATHOL RES PRACT, V193, P1
[23]  
Hofmockel G, 1996, ANTICANCER RES, V16, P3807
[24]  
HOFMOCKEL G, 1995, CANCER, V76, P296, DOI 10.1002/1097-0142(19950715)76:2<296::AID-CNCR2820760221>3.0.CO
[25]  
2-L
[26]  
Jochum W, 1996, CANCER, V77, P514
[27]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[28]   NEW ANTISERUM AGAINST KI-67 ANTIGEN SUITABLE FOR DOUBLE IMMUNOSTAINING OF PARAFFIN WAX SECTIONS [J].
KEY, G ;
PETERSEN, JL ;
BECKER, MHG ;
DUCHROW, M ;
SCHLUTER, C ;
ASKAA, J ;
GERDES, J .
JOURNAL OF CLINICAL PATHOLOGY, 1993, 46 (12) :1080-1084
[29]  
Lai R, 1996, MODERN PATHOL, V9, P690
[30]   PROGNOSTIC FACTORS IN RENAL-CELL CARCINOMA [J].
LANIGAN, D .
BRITISH JOURNAL OF UROLOGY, 1995, 75 (05) :565-571